CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
The new online Learning Center with new content can still be found under the “Training” folder on ...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...